/ORKA
ORKA Stock - Oruka Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$31.84+13.11%
+$3.69 (+13.11%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+75.1%upside
Target: $55.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ORKA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$31.52 – $32.16
TARGET (TP)$55.75
STOP LOSS$29.29
RISK/REWARD1:9.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.46
52W High$32.28
52W Low$5.49
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-27,000 | $-111,000 | $-114,000 | $-91,000 | $-93,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-88,123,000 | $-7,296,000 | $-9,841,000 | $-19,335,000 | $-9,766,000 |
| Net Income | $-83,724,000 | $-5,339,000 | $-9,926,000 | $-19,322,000 | $-9,738,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-4.99 | $-4.44 | $-8.27 | $-16.68 | $-8.40 |
Company Overview
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish0 Neutral/Bearish
Price Targets
$47
Average Target
↑ 47.6% Upside
Now
$20
Low
$47
Average
$75
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Piper Sandler | Initiation | Overweight | $75 |
| November 13th 2025 | Jefferies | Initiation | Buy | $45 |
| October 27th 2025 | Guggenheim | Initiation | Buy | $60 |
| October 13th 2025 | Barclays | Initiation | Overweight | $48 |
| May 22nd 2025 | BTIG Research | Initiation | Buy | $44 |
| February 4th 2025 | Wolfe Research | Initiation | Outperform | $20 |
| October 11th 2024 | Stifel | Initiation | Buy | $49 |
| October 7th 2024 | H.C. Wainwright | Initiation | Buy | $45 |
| September 17th 2024 | Leerink Partners | Initiation | Outperform | $44 |
| September 16th 2024 | TD Cowen | Initiation | Buy | - |
| September 13th 2024 | Jefferies | Initiation | Buy | $40 |
Earnings History & Surprises
ORKABeat Rate
75%
Last 8 quarters
Avg Surprise
-1.1%
EPS vs Estimate
Beats / Misses
6/2
Last 12 quarters
Latest EPS
$-0.55
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q4 24
-265.0%
$-1.46vs$-0.40
Q1 25
-41.2%
$-0.96vs$-0.68
Q2 25
+29.8%
$-0.40vs$-0.57
Q3 25
+4.2%
$-0.46vs$-0.48
Q4 25
+1.8%
$-0.55vs$-0.56
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.61 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.56 | $-0.55 | +1.8% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.48 | $-0.46 | +4.2% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.57 | $-0.40 | +29.8% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.68 | $-0.96 | -41.2% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.40 | $-1.46 | -265.0% | ✗ MISS |
Q3 2024 | Aug 27, 2024 | — | $-1.88 | — | — |
Q2 2024 | Apr 25, 2024 | — | $-0.14 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.08 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.10 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.10 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.09 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.98 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-1.94 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-2.62 | — | — |
Q1 2022 | Mar 31, 2022 | $-26.88 | $-2.72 | +89.9% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-4.73 | — | — |
Q3 2021 | Sep 30, 2021 | $-27.60 | $-3.92 | +85.8% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | $-28.44 | $-4.03 | +85.8% | ✓ BEAT |
Latest News
Piper Sandler Initiates Coverage On Oruka Therapeutics with Overweight Rating, Announces Price Target of $75
📈 PositiveBenzinga•Dec 18, 2025, 12:32 PM
Jefferies Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $45
📈 PositiveBenzinga•Nov 13, 2025, 12:39 PM•Also:
BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $63
📈 PositiveBenzinga•Nov 13, 2025, 10:08 AM
Oruka Therapeutics Q3 EPS $(0.55) Beats $(0.59) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:45 PM
Guggenheim Initiates Coverage On Oruka Therapeutics with Buy Rating, Announces Price Target of $60
📈 PositiveBenzinga•Oct 27, 2025, 11:54 AM
HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Lowers Price Target to $40
➖ NeutralBenzinga•Oct 27, 2025, 10:59 AM
Barclays Initiates Coverage On Oruka Therapeutics with Overweight Rating, Announces Price Target of $48
📈 PositiveBenzinga•Oct 13, 2025, 12:07 PM•Also:
Oruka Therapeutics Files For Mixed Shelf Of Up To $500M
📈 PositiveBenzinga•Oct 3, 2025, 09:32 PM
Oruka Therapeutics shares are trading higher. BTIG reiterated its Buy rating on the stock and maintained its $56 price target.
📈 PositiveBenzinga•Sep 29, 2025, 06:09 PM
BTIG Reiterates Buy on Oruka Therapeutics, Maintains $56 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 10:21 AM
Clear Street Maintains Buy on Oruka Therapeutics, Maintains $46 Price Target
📈 PositiveBenzinga•Sep 17, 2025, 01:54 PM
Oruka Therapeutics shares are trading higher after the company announced interim Phase 1 results for ORKA-001. Also, the company announced a $180 million private placement.
📈 PositiveBenzinga•Sep 17, 2025, 12:51 PM
Oruka Therapeutics Interim Phase 1 Data Shows ORKA-001 Achieves Sustained STAT3 Inhibition With Favorable Tolerability And Safety Profile
📈 PositiveBenzinga•Sep 17, 2025, 06:13 AM
Oruka Therapeutics Secures $180M Private Placement To Advance Chronic Skin Disease Biologics And Fund Research And Development
📈 PositiveBenzinga•Sep 17, 2025, 06:12 AM
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 11:10 AM
Frequently Asked Questions about ORKA
What is ORKA's current stock price?
Oruka Therapeutics, Inc. (ORKA) is currently trading at $31.84 per share. The stock has moved +13.11% today.
What is the analyst price target for ORKA?
The average analyst price target for ORKA is $55.75, based on 1 analyst.
What sector is Oruka Therapeutics, Inc. in?
Oruka Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ORKA's market cap?
Oruka Therapeutics, Inc. has a market capitalization of $1.19 billion, making it a small-cap company.
Does ORKA pay dividends?
No, Oruka Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
MNMD
Mind Medicine (MindMed) Inc.
$12.70
Mkt Cap: $1.0B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
RAPP
Rapport Therapeutics, Inc. Common Stock
$30.85
Mkt Cap: $1.1B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to ORKA for comparison